Edwards Lifesciences‘s Evoque tricuspid valve replacement system reduces tricuspid heart valve leakage to non-traceable or mild leakage in 98% of patients, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session.
Evoque is designed to replace native tricuspid valves without open-heart surgery. The valve is implanted using a minimally invasive delivery system where a doctor places a thin tube through a vein in the leg to reach the patient’s heart and perform the valve replacement procedure.
Get the full story on our sister site, Medical Design & Outsourcing.